On the morning of January 17th, Li Hui, vice-chairman of the platform, and his party went to Beijing to visit Professor Guo Zikuan, MD, a researcher of China Academy of Military Medical Sciences, to have an exchange and consultation on the development prospect of cell field in biomedical industry.pictureMr. Li Hui said that the platform, as the third party to attract investment from the government industry, not only manages its own industry well, but also undertakes the mission of providing industry consultation for the government and attracting high-quality projects to develop. Henan Province is located in the Central Plains with a large population. It has natural resources and market advantages in developing biomedical industry, but the current development situation is still unsatisfactory. The purpose of this visit to Professor Guo is to hope that the professor can give professional guidance and help us answer questions.Professor Guo analyzed the current market situation of biomedicine, especially in the field of cells, and gave constructive suggestions on the current policy development direction and scientific research results. Professor Guo said that to develop the biomedical industry, we should follow three principles, one is to conform to scientific principles, the other is that individual cases do not represent groups, and the third is statistical principles. In the current complicated market environment, we should combine our own actual situation, change our thinking in time, and choose the industrial fields suitable for the current development. Professor Guo also recommended some high-quality projects according to Henan's resource advantages.pictureProfessor Guo Zikuan is the executive deputy editor of journal of experimental hematology, the executive editor of China Journal of Tissue Engineering, and the editorial boards of World Journal of Stem Cells, Chinese Journal of Cell Stem Cells and Journal of Tissue Engineering and Reconstructive Surgery. Graduated from Beijing Medical University, majoring in internal medicine and hematology, and has been engaged in basic and clinical trials of cell therapy in recent years. He was in charge of three national "863" projects, three national natural science foundation projects and participated in many national projects. In cooperation with a number of hospitals, clinical trials have been carried out in the treatment of acute myeloid leukemia with NK cells, prevention and treatment of graft-versus-host disease with mesenchymal stem cells, treatment of tumor with immune cells, treatment of femoral head necrosis with autologous stem cells, and treatment of vitiligo with epidermal cell transplantation. He has published more than 30 international papers by newsletter or the first author, and obtained 11 national invention patents. He is good at the design and implementation of clinical trials of cell therapy, and has his own unique views on immunotherapy of leukemia, aplastic anemia and solid tumors, as well as cell transplantation for refractory orthopedic and skin diseases.
.png)
